Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 1/2015

01-02-2015

Pemetrexed Ameliorates Experimental Arthritis in Rats

Authors: Ahmet Karatas, Suleyman Serdar Koca, Metin Ozgen, Adile Ferda Dagli, Fazilet Erman, Nuran Sahin, Kazim Sahin, Ahmet Isik

Published in: Inflammation | Issue 1/2015

Login to get access

Abstract

Pemetrexed (PMTX) is an anti-folate drug as methotrexate. The purpose of this study was to assess the efficacy of PMTX on collagen-induced arthritis (CIA). Forty Wistar albino rats were randomized into four groups. Arthritis was induced by intradermal injection of chicken type II collagen combined with incomplete Freund’s adjuvant. Animals were sacrificed at the 15th day after the onset of arthritis. Tumor necrosis factor alpha (TNF-α), interleukin (IL)-17, and malondialdehyde (MDA) levels were increased, and superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activities and the expressions of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) were decreased in the arthritis group. In the PMTX-treated (0.2 and 1 mg/kg/week i.p.) groups, the levels of TNF-α, IL-17, and MDA were decreased; the activities of SOD, CAT, and GPx and the expressions of Nrf2 and HO-1 were restored, and perisynovial inflammation and cartilage–bone destruction were decreased. PMTX has anti-arthritic potential in the CIA model and may be a therapeutic agent for rheumatoid arthritis.
Literature
1.
Hobbs, K.F., and M.D. Cohen. 2012. Rheumatoid arthritis disease measurement: A new old idea. Rheumatology (Oxford) 51: vi21–27.CrossRef
2.
Schett, G., and E. Gravallese. 2012. Bone erosion in rheumatoid arthritis: Mechanisms, diagnosis and treatment. Nature Reviews. Rheumatology 8(11): 656–664.CrossRefPubMedCentralPubMed
3.
Breedveld, F.C., M.H. Weisman, A.F. Kavanaugh, S.B. Cohen, K. Pavelka, R. van Vollenhoven, et al. 2006. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis and Rheumatism 54(1): 26–37.CrossRefPubMed
4.
Shih, C., V.J. Chen, L.S. Gossett, S.B. Gates, W.C. MacKellar, L.L. Habeck, et al. 1997. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Research 57(6): 1116–1123.PubMed
5.
Vogelzang, N.J., J.J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffie, et al. 2003. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 21(14): 2636–2644.CrossRefPubMed
6.
Cohen, M.H., R. Justice, and R. Pazdur. 2009. Approval summary: Pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. The Oncologist 14(9): 930–935.CrossRefPubMed
7.
Williams, R.O. 2004. Collagen-induced arthritis as a model for rheumatoid arthritis. Methods in Molecular Medicine 98: 207–216.PubMed
8.
Lawson, B.R., S.M. Belkowski, J.F. Whitesides, P. Davis, and J.W. Lawson. 2007. Immunomodulation of murine collagen-induced arthritis by N, N-dimethylglycine and a preparation of Perna canaliculus. BMC Complementary and Alternative Medicine 7: 20.CrossRefPubMedCentralPubMed
9.
Trentham, D.E., A.S. Townes, and A.H. Kang. 1977. Autoimmunity to type II collagen an experimental model of arthritis. Journal of Experimental Medicine 146(3): 857–868.CrossRefPubMed
10.
Larsson, P., S. Kleinau, R. Holmdahl, and L. Klareskog. 1990. Homologous type II collagen-induced arthritis in rats. Characterization of the disease and demonstration of clinically distinct forms of arthritis in two strains of rats after immunization with the same collagen preparation. Arthritis and Rheumatism 33(5): 693–701.CrossRefPubMed
11.
Barsante, M.M., E. Roffe, C.M. Yokoro, W.L. Tafuri, S.G. Souza, V. Pinho, et al. 2005. Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. European Journal of Pharmacology 516(3): 282–289.CrossRefPubMed
12.
Choi, J., B.J. Yoon, Y.N. Han, K.T. Lee, J. Ha, H.J. Jung, et al. 2003. Antirheumatoid arthritis effect of Rhus verniciflua and of the active component, sulfuretin. Planta Medica 69(10): 899–904.CrossRefPubMed
13.
Lowry, O.H., N.J. Rosebrough, A.L. Farr, and R.J. Randall. 1951. Protein measurement with the folin phenol reagent. Journal of Biological Chemistry 193: 165–175.
14.
Sokka, T. 2003. Work disability in early rheumatoid arthritis. Clinical and Experimental Rheumatology 21(5 Suppl 31): S71–74.PubMed
15.
Young, A., G. Koduri, M. Batley, E. Kulinskaya, A. Gough, S. Norton, et al. 2007. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 46(2): 350–357.CrossRef
16.
Finckh, A., N. Bansback, C.A. Marra, A.H. Anis, K. Michaud, S. Lubin, et al. 2009. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: A cost-effectiveness analysis. Annals of Internal Medicine 151(9): 612–621.CrossRefPubMed
17.
Nam, J.L., K.L. Winthrop, R.F. van Vollenhoven, K. Pavelka, G. Valesini, E.M. Hensor, et al. 2010. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of RA. Annals of the Rheumatic Diseases 69(6): 976–986.CrossRefPubMed
18.
Lu, L.J., C.D. Bao, M. Dai, J.L. Teng, W. Fan, F. Du, et al. 2009. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis and Rheumatism 61(7): 979–987.CrossRefPubMed
19.
Fan, P.T., and K.H. Leong. 2007. The use of biological agents in the treatment of rheumatoid arthritis. Annals of the Academy of Medicine, Singapore 36(2): 128–134.PubMed
20.
Xinqiang, S., L. Fei, L. Nan, L. Yuan, Y. Fang, X. Hong, et al. 2010. Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+CD25+ Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Biomedicine and Pharmacotherapy 64(7): 463–471.CrossRefPubMed
21.
Chattopadhyay, S., R.G. Moran, and I.D. Goldman. 2007. Pemetrexed: Biochemical and cellular pharmacology, mechanisms, and clinical applications. Molecular Cancer Therapeutics 6(2): 404–417.CrossRefPubMed
22.
Niimoto, T., T. Nakasa, M. Ishikawa, A. Okuhara, B. Izumi, M. Deie, et al. 2010. MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskeletal Disorders 11: 209.CrossRefPubMedCentralPubMed
23.
Miranda-Carus, M.E., A. Balsa, M. Benito-Miguel, C. Perez de Ayala, and E. Martin-Mola. 2004. IL-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: Effect of methotrexate. Journal of Immunology 173(2): 1463–1476.CrossRef
24.
Manicourt, D.H., R. Triki, K. Fukuda, J.P. Devogelaer, C. Nagant de Deuxchaisnes, and E.J. Thonar. 1993. Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis and Rheumatism 36(4): 490–499.CrossRefPubMed
25.
Seitz, M., M. Zwicker, and P.M. Villiger. 2003. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different American college of rheumatology response groups to methotrexate. Journal of Rheumatology 30(1): 28–35.PubMed
26.
27.
Halliwell, B., J.R. Hoult, and D.R. Blake. 1988. Oxidants, inflammation, and anti-inflammatory drugs. FASEB Journal 2(13): 2867–2873.PubMed
28.
Imadaya, A., K. Terasawa, H. Tosa, M. Okamoto, and K. Toriizuka. 1988. Erythrocyte antioxidant enzymes are reduced in patients with rheumatoid arthritis. Journal of Rheumatology 15(11): 1628–1631.PubMed
29.
Nivsarkar, M. 2000. Improvement in circulating superoxide dismutase levels: Role of nonsteroidal anti-inflammatory drugs in rheumatoid arthritis. Biochemical and Biophysical Research Communications 270(3): 714–716.CrossRefPubMed
30.
Rasool, M., and P. Varalakshmi. 2007. Protective effect of Withania somnifera root powder in relation to lipid peroxidation, antioxidant status, glycoproteins and bone collagen on adjuvant-induced arthritis in rats. Fundamental and Clinical Pharmacology 21(2): 157–164.CrossRefPubMed
31.
Kerimova, A.A., M. Atalay, E.Y. Yusifov, S.P. Kuprin, and T.M. Kerimov. 2000. Antioxidant enzymes; possible mechanism of gold compound treatment in rheumatoid arthritis. Pathophysiology 7(3): 209–213.CrossRefPubMed
32.
Salvemini, D., E. Mazzon, L. Dugo, I. Serraino, A. De Sarro, A.P. Caputi, et al. 2001. Amelioration of joint disease in a rat model of collagen-induced arthritis by M40403, a superoxide dismutase mimetic. Arthritis and Rheumatism 44(12): 2909–2921.CrossRefPubMed
33.
Dalle-Donne, I., R. Rossi, D. Giustarini, A. Milzani, and R. Colombo. 2003. Protein carbonyl groups as biomarkers of oxidative stress. Clinica Chimica Acta 329(1–2): 23–38.CrossRef
34.
Girotti, A.W. 1998. Lipid hydroperoxide generation, turnover, and effector action in biological systems. Journal of Lipid Research 39(8): 1529–1542.PubMed
35.
Garg, N., R. Singh, J. Dixit, A. Jain, and V. Tewari. 2006. Levels of lipid peroxides and antioxidants in smokers and nonsmokers. Journal of Periodontal Research 41(5): 405–410.CrossRefPubMed
36.
Kamanli, A., M. Naziroglu, N. Aydilek, and C. Hacievliyagil. 2004. Plasma lipid peroxidation and antioxidant levels in patients with rheumatoid arthritis. Cell Biochemistry and Function 22(1): 53–57.CrossRefPubMed
37.
Bauerova, K., E. Paulovicova, D. Mihalova, F. Drafi, M. Strosova, C. Mascia, et al. 2010. Combined methotrexate and coenzyme Q(1)(0) therapy in adjuvant-induced arthritis evaluated using parameters of inflammation and oxidative stress. Acta Biochimica Polonica 57(3): 347–354.PubMed
38.
Hayes, J.D., and A.T. Dinkova-Kostova. 2014. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends in Biochemical Sciences 39(4): 199–218.CrossRefPubMed
39.
Wruck, C.J., A. Fragoulis, A. Gurzynski, L.O. Brandenburg, Y.W. Kan, K. Chan, et al. 2011. Role of oxidative stress in rheumatoid arthritis: Insights from the Nrf2-knockout mice. Annals of the Rheumatic Diseases 70: 844–850.CrossRefPubMed
40.
Maicas, N., M.L. Ferrándiz, R. Brines, L. Ibáñez, A. Cuadrado, M.I. Koenders, W.B. van den Berg, and M.J. Alcaraz. 2011. Deficiency of Nrf2 accelerates the effector phase of arthritis and aggravates joint disease. Antioxidants and Redox Signaling 15(4): 889–901.CrossRefPubMed
Metadata
Title
Pemetrexed Ameliorates Experimental Arthritis in Rats
Authors
Ahmet Karatas
Suleyman Serdar Koca
Metin Ozgen
Adile Ferda Dagli
Fazilet Erman
Nuran Sahin
Kazim Sahin
Ahmet Isik
Publication date
01-02-2015
Publisher
Springer US
Published in
Inflammation / Issue 1/2015
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-0002-3

Other articles of this Issue 1/2015

Inflammation 1/2015 Go to the issue

OriginalPaper

Potential Effects of Calcium Binding Protein S100A12 on Severity Evaluation and Curative Effect of Severe Acute Pancreatitis

OriginalPaper

Oral Administration of Saccharomyces boulardii Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis in Rats via Reducing Intestinal Permeability and Modulating Gut Microbial Composition

OriginalPaper

Propofol Attenuates Lipopolysaccharide-Induced Reactive Oxygen Species Production Through Activation of Nrf2/GSH and Suppression of NADPH Oxidase in Human Alveolar Epithelial Cells

OriginalPaper

NS5ATP9 Suppresses Activation of Human Hepatic Stellate Cells, Possibly via Inhibition of Smad3/Phosphorylated-Smad3 Expression

OriginalPaper

Lipoxin A4 Suppresses Lipopolysaccharide-Induced Hela Cell Proliferation and Migration via NF-κB Pathway

OriginalPaper

Trans-Resveratrol Attenuates High Fatty Acid-Induced P2X7 Receptor Expression and IL-6 Release in PC12 Cells: Possible Role of P38 MAPK Pathway
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits